Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 163 participants.
Also called NCT04927299
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 163 participants
- Registry
-
NCT04927299
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Mexico
- Registry status
- Completed
Technical summary
Registry record NCT04927299. Randomized; double masking; primary purpose treatment. Start 2022-06-30 (actual); primary completion 2023-08-15 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension
- Condition
- Essential Arterial Hypertension
- Intervention (Drug)
- Losartan/Chlorthalidone in fixed dose
- Intervention (Drug)
- Losartan + hydrochlorothiazide in fixed dose
- Lead sponsor
- Laboratorios Silanes S.A. de C.V.
Record details
- Record id
cardio:ct-nct04927299- Content hash
00302eb90f56f45e4f7648407aba12e6bd194620f246d5aa1687e0cc3e19791e